Citations

Clear

941 citation(s) found for "Tan, MH".

Clinical Criteria for the Definition of Refractory Septic Shock: A Joint Delphi Consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM)
Myatra, Sheila Nainan , Dugar, Siddharth , Russell, Lene , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S. , Gong, Michelle N. , Hernández, Glenn , Martín‐Loeches, Ignacio , Dünser, Martin W., Einav, Sharon , Hamzaoui, Olfa, Frazee, Erin N. , Busse, Laurence W. , Deutschman, Clifford S. , Holder, Andre L. , Nazer, Lama , Nunnally, Mark , Rincon, Teresa , Seymour, Christopher W. , Besen, Bruno Adler Maccagnan Pinheiro , Finfer, Simon , Machado, Flávia Ribeiro , Mer, Mervyn , Young, Paul J. , Khanna, Ashish , Dugar, Siddharth , Wieruszewski, Patrick M , Russell, Lene , Evans, Laura , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S , Gong, Michelle Ng , Hernández, Glenn , Schorr, Christa , Lakbar, Ines , Smith, Susan E , Martin-Loeches, Ignacio , Annane, Djillali , Balik, Martin , Cecconi, Maurizio , De Backer, Daniel , Donadello, Katia , Einav, Sharon , Ferrer, Ricard , Juffermans, Nicole , Hamzaoui, Olfa , Landoni, Giovanni , Levy, Bruno , McKenzie, Cathrine , Monnet, Xavier , Ostermann, Marlies , Spies, Claudia D , Singer, Mervyn , Theodorakopulou, Maria , Topeli, Arzu , Frazee, Erin N , Bauer, Seth R , Busse, Laurence W , Coopersmith, Craig M , Deutschman, Clifford , Holder, Andre L , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S , Maves, Ryan C , Nazer, Lama , Nunnally, Mark E , Prescott, Hallie C , Rincon, Teresa , Sacha, Gretchen , Seymour, Chris W , Arabi, Yaseen M , Besen, Bruno Amp , Cavalcanti, Alexandre Biasi , Deane, Adam M , Finfer, Simon , Hammond, Naomi , Ibarra-Estrada, Miguel , Kattan, Eduardo , Kotani, Yuki , Machado, Flavia R , Ospina-Tascón, Gustavo A , Mer, Mervyn , Young, Paul J , Rochwerg, Bram , Khanna, Ashish K , Léone, Marc , Wieruszewski, Patrick M. , Smith, Susan , Backer, Daniel De , Dünser, Martin W. , Lévy, Bruno , McKenzie, Cathrine , Ostermann, Marlies , Spies, Claudia , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S. , Maves, Ryan C. , Prescott, Hallie C. , Arabi, Yaseen M. , Deane, Adam M. , Hammond, Naomi

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 5 | Pages: 1073-1091

10.1097/ccm.0000000000007124 | PMID 41873857 Get It

OBJECTIVE: A definition of refractory septic shock is necessary to guide diagnosis, management, prognostication, research, and future guidelines for this most severe form of the disease. We sought to achieve consensus on clinical criteria that would be used to define refractory septic shock. DESIGN: Review of literature, expert panel position statements, and Delphi rounds with an international expert group. SETTING: Consensus was defined as having at least 75% of panellists in agreement or disagreement on the three highest or lowest levels of a 7-point Likert scale or based on responses to single- or multiple-choice questions, respectively. SUBJECTS: A panel of multinational, multiprofessional and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine (57 invitations and 56 participants). MEASUREMENTS AND MAIN RESULTS: A five-round Delphi process was conducted for consensus and stability. The steering committee proposed 34 statements, and five of them were rejected by panel experts after round 2. Among 29 statements selected from eight domains, consensus was reached for 13. The panel agreed on the need for a comprehensive consensus set of clinical criteria for refractory septic shock. Markers of organ dysfunction (75%, 2 rounds), tissue perfusion (91.1%, 2 rounds) including lactate (94.6%, 2 rounds) and capillary refill time (76.8%, 2 rounds), assessment of fluid-responsiveness after initial resuscitation (92.9%, 5 rounds), and use of vasoactive drugs at norepinephrine equivalents greater than 0.5 µg/kg/min (75.0%, 3 rounds), were selected as clinical criteria of refractory septic shock. The use of critical care ultrasound (CCUS) (92.9%, 3 rounds) was the single diagnostic modality that reached a consensus-based agreement. CONCLUSIONS: A consensus for 13 criteria to frame the definition of refractory septic shock was reached. Refractory septic shock is characterised by persistently elevated lactate concentrations and or prolonged capillary refill time in patients with septic shock who are fluid unresponsive, require a norepinephrine base equivalent dose greater than 0.5 micrograms per kilogram per minute, and undergo CCUS assessment when mixed shock is suspected.
The Association of Extended Venous Thromboembolism Prophylaxis and Venous Thromboembolism After Cancer Surgery
Tan, Po Hong, Lillemoe, Keith D., Stucky, Chee-Chee, Brady, Justin T., Pockaj, Barbara A. , Cronin, Patricia, Potter, Alexandra L. , Yang, Chi-Fu Jeffrey, Mavros, Michail N., Fagenholz, Peter J. , Kastrinakis, William V., Poruk, Katherine E. , Wasif, Nabil , Qadan, M., Pockaj, Barbara, Poruk, Katherine, Fong, Zhi Ven , Lillemoe, Keith D. , Stucky, Chee-Chee, Brady, Justin T. , Cronin, Patricia, Linderman, George C. , Yang, Chi‐Fu Jeffrey , Mavros, Michail N. , Thiels, Cornelius A. , Habermann, Elizabeth B. , Chang, Yu‐Hui , Qadan, Motaz

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 19, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.7128 | PMID 41911913 Get It

Background: ASCO recommends extended venous thromboembolism (VTE) prophylaxis with low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) following cancer surgery. However, these recommendations were based on trials using routine venography, which detects asymptomatic VTEs, and real-life efficacy is not well studied. We aimed to assess the association of extended VTE prophylaxis with the incidence of clinically significant VTE after elective cancer surgery. Patients and Methods: In this retrospective, population-based cohort study, we identified patients who underwent surgical resection for lung, breast, esophageal, gastric, pancreas, and colon cancer from 2010 to 2017 using the SEER–Medicare linked dataset. Patients were divided into 1 of 2 main groups for comparative analyses: those who received extended VTE prophylaxis after cancer surgery and those who did not. Patients who received extended VTE prophylaxis after cancer surgery were identified as those prescribed prophylactic doses of LMWH or a DOAC within 7 days of discharge, as captured in Medicare Part D files. Results: A total of 113,739 Medicare beneficiaries were identified, of whom 1,570 (1.4%) received extended VTE prophylaxis. There was a year-over-year increase in the use of extended VTE prophylaxis during the study period, rising from 0.6% in 2010 to 3.3% in 2017. The overall incidence of VTE was 1.6% at 1 month, 4.3% at 6 months, 5.7% at 12 months, with significant differences observed across cancer types ( P <.001). However, patients who received extended VTE prophylaxis had a higher 1-year cumulative incidence of postoperative VTE compared with those who did not (11.4% vs 5.3%; P <.001), an association that was consistent across cancer sites. In adjusted analyses, extended VTE prophylaxis was independently associated with an increased risk of VTE (hazard ratio, 1.6; 95% CI, 1.3–2.0; P <.001). Extended prophylaxis was also associated with a higher 1-year incidence of bleeding events compared with patients who did not receive prophylaxis (12.0% vs 8.5%; P <.001). Conclusions: The utilization of extended VTE prophylaxis after cancer surgery remains low, although it has increased every year. Paradoxically, patients who received extended VTE prophylaxis had higher incidences of clinically significant VTE and bleeding compared with those who did not, likely reflecting patient selection and surveillance bias after surgery. In light of these findings, national guidelines recommending postoperative extended VTE prophylaxis, and its use as a surrogate for quality of care, should continue to be re-examined.
Conversational AI to improve preventive care in rural America: co-designing with healthcare providers and parent-adolescent dyads
Argyris, Young Anna , Town, Mya, Darr, Francis J. A. , Klee, David , Winn, Brian , English, B. Keith , Tan, Pang-Ning , Kordjamshidi, Parisa , Gogineni, Kamalika , Klee, David, Winn, Brian , Jacobson, Robert M. , Tan, Pang-Ning

Mayo Clinic

BMJ Innovations | March 19, 2026 | Volume: 12 | Issue: 3 | Pages: 234-239

10.1136/bmjinnov-2025-001473 Get It

Background While rural health guidelines have often cautioned against digital interventions due to infrastructure and literacy barriers, this study introduces an SMS-based conversational artificial intelligence (CAI) that overcomes these limitations to promote HPV vaccination. Objective To evaluate an SMS-based CAI using the Centers for Disease Control (CDC)’s presumptive and CASE (Corroborate, About Me, Science and Explain) frameworks to promote HPV vaccination among rural parent-adolescent dyads by: (1) testing its usability; (2) assessing the feasibility of co-design with clinicians and parent-adolescents; (3) identifying adoption barriers and (4) examining communication preferences across behavioural profiles. Methods We developed a CAI simulator using the presumptive approach and the structured CASE method to address 11 common concerns about the HPV vaccine. A multimethod usability study with 13 rural parent-adolescent dyads (n=26) included in-depth interviews and the System Usability Scale. Results The CAI achieved excellent usability (mean SUS 85.2, ~96th percentile). A previously undocumented behavioural profile—vaccine-unaware—was identified, distinct from hesitancy, and best addressed through empathetic, exploratory dialogue. Key adoption barriers included integration with existing preventive care routines and endorsement by trusted local providers. Conclusions Contrary to the assumption that rural residents resist digital tools, participants engaged readily when content was credible, locally endorsed and accessible via SMS. Findings highlight the conditional effectiveness of the CDC’s presumptive style in CAIs—well-suited for vaccine-compliant users but less effective for sceptical or unaware groups, who, we argue, would respond better to conversational, empathetic tones.
Artificial intelligence modelling in grading breast phyllodes tumours
Koong, Jessica Ee Ting , Shafique, Abubakr , Nasir, Nur Diyana Md , Han, Aaron C., Harada, Oi , Lee, Cheok Soon , Nishimura, Rieko , Ohi, Yasuyo , Tizhoosh, H. R., Tan, Puay Yok, Tizhoosh, Hamid R. , Md Nasir, Nur Diyana , Han, Aaron , Lee, Soon , Tizhoosh, Hamid R , Tan, Puay Hoon

Mayo Clinic

Histopathology | March 19, 2026 | Volume: 89 | Issue: 2 | Pages: 383-389

10.1111/his.70144 | PMID 41853872 Get It

Background Breast phyllodes tumours (PT) are rare biphasic neoplasms consisting of epithelial and stromal components. They are classified into benign, borderline and malignant categories. Diagnosing and grading PTs present a challenge for pathologists, as there are multiple histological parameters and their own tiers. We aim to investigate the potential role of artificial intelligence (AI) as a diagnostic aid in determining PT grade. Materials and methods We investigated 15 PT whole slide images (WSIs), comprising 5 benign, 5 borderline and 5 malignant cases. We sought to classify and retrieve the most relevant WSIs by matching histological features at different patch sizes, using the Yottixel framework for WSI processing. Patches were extracted at a 20× magnification level. We then used the KimiaNet to extract feature vectors and transformed these into barcode representations. Barcodes of a query WSI were compared with those of others in the archive, allowing us to identify the most similar WSI and determine the PT grades from histological similarities. Results We utilized ‘majority‐n accuracy’ as a measure of correctness, that is when the majority of the top‐n search results have the correct diagnosis as the query patient. We achieved a maximum reported accuracy of 67%, with a 3000 × 3000 patch size when grading PT at majority voting with n = 4. Conclusion Despite the small sample size and absence of fine‐tuning, our study demonstrated the potential of AI‐based PT grade stratification using various patch sizes through histological matching. This serves as a preliminary proof of concept, with the prospect of refinement for potential routine clinical application.
LGG-10. Diffuse leptomeningeal glioneuronal tumor: a comprehensive clinical and molecular analysis
Mikkelsen, Margit , Li, Xiaoyu, Yu, Kaiwen, High, Anthony A. , Tan, Haiyan, Furtado, Larissa V. , Berry, Julia D., Boué, Daniel R. , Chien, Franklin , Dewan, Michael, Hoffman, Lindsey, Kofler, Julia , Larkin, Trisha , May, Adriana , Noun, Dolly , Schwartz, Jonathan, Sheila, Ivanna, Spiller, Susan, Tanak, Ryuma, Robinson, Giles W, Peng, Junmin, Chiang, Jason, Moreira, Daniel, Li, Xiaoyu, Leelatian, Nalin , Bell, Jessica, Coven, Scott L. , Dewan, Michael Christopher , Foster, Jessica , Hoffman, Lindsey M. , Lazow, Margot , Mobley, Bret C. , Posorske, Benjamin , Schwartz, Jonathan , Qaddoumi, Ibrahim A. , Chiang, Jason

Mayo Clinic

Neuro-Oncology Pediatrics | March 12, 2026 | Volume: 1 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuaf001.193 Get It

Abstract Diffuse leptomeningeal glioneuronal tumors (DLGNT) are rare central nervous system tumors. Our understanding of the clinical course, prognostic factors, and optimal treatment strategies remains limited. Histologic, molecular, and clinical data were collected and analyzed for 25 patients with DLGNT reviewed at St. Jude Children’s Research Hospital. The median age at diagnosis was 6 years (11 months-20 years). Nineteen (72%) patients were male. The disease was localized at diagnosis in 12 (48.0%) patients, with most tumors localized in the spinal cord. BRAF fusion was present in 22 (95.6%) of 23 patients who had material for testing. Of 18 patients who had tissue for DNA methylation profiling, 3 (16.7%) matched to DLGNT MC-1, 3 (16.7%) to DLGNT MC-2, and 12 (66.7%) did not match to a DLGNT subclass. Median follow-up was 63 months. Twenty-four (96.0%) patients received adjuvant therapy after initial diagnosis or at progression. Thirty-five cytotoxic chemotherapy and 24 single-agent targeted therapy regimens were used in 22 and 13 patients, respectively. With targeted therapy, 3 (12%) patients had partial responses. Eleven (44.0%) received radiotherapy. Median progression-free survival (PFS) after a patient’s first chemotherapy, targeted therapy, or radiotherapy regimen was 44 months (1-77), 11 months (4-39), and 16.5 months (9-23), respectively. The 5-year PFS was 18.7%±9.2, while the 5-year overall survival (OS) was 82.4%±9.2. The 5-year OS was lower in patients older than 9 years at diagnosis (60.0%±21.9 vs 91.7%±8.0, p = 0.02). Ki67 &gt;4% was associated with worse PFS (0%±0 vs 24.6%±11.9 at 5 years, p = 0.03). Initial disease dissemination (localized vs. disseminated) and 1q gain status do not influence PFS or OS. PFS for DLGNT remains poor across all treatment modalities, including targeted therapies, despite the high frequency of BRAF fusions. Due to its rarity, establishing optimal therapeutic strategies for DLGNT requires additional treatment and outcome data and prospective multi-institutional trials.
Stroke burden in the Philippines (1990–2023): Temporal trends and risk factors from the GBD study
Lescano, Judah Israel Ong , Belangoy, Keith Pardillada , Vu, Quynh Thi , OUDDOUD, Hanane , Arce, Florencio V., Tan, Elizabeth Y, Iwata, Naohiro, Takeda, Tatsuaki , Zamami, Yoshito , Koyama, Toshihiro, Lescano, Judah Israel , Nishimura, Yoshito , Harada, Ko , Hagiya, Hideharu , See, Gerard Lee , Arce, Florencio, Tan, Elizabeth , Iwata, Naohiro, Koyama, Toshihiro

Mayo Clinic

No container title available | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.04.26347658 Get It

Abstract Background Stroke is a leading cause of mortality and disability globally. However, information about stroke burden in the Philippines is limited. We sought to analyze stroke burden in the Philippines from 1990 to 2023. Methods Incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) estimates from the Global Burden of Disease Study 2023 data were used as indicators to analyze the burden of stroke by sex and age. Temporal trends in both crude and age-standardized rates were analyzed using joinpoint regression analysis. Results In 2023, stroke incidence was estimated at 156.2 (95% uncertainty interval [UI]: 140.8–175.4) thousand, prevalence at 1.2 (95% UI: 1.2–1.4) million, mortality at 72.2 (95% UI: 63.2–83.0) thousand, and DALYs at 2.1 (95% UI: 1.8–2.3) million. High systolic blood pressure was the leading contributor to risk-attributable stroke mortality and DALYs. Since 1990, age-standardized rates declined significantly, whereas crude rates increased markedly. Compared with women, men had a higher fatal burden and consistently exhibited a higher age-standardized burden. Although older adults (≥ 55 years) had the highest stroke burden and achieved reductions in stroke incidence and fatal outcomes, both fatal and non-fatal burdens consistently increased among young adults (35–54 years). Conclusion While age-standardized rates have improved, the rising crude burden and shift towards younger adults present significant public health challenges. These trends highlight the pressing need for aggressive and targeted risk factor control, sustained risk monitoring, and strengthened acute and post-stroke care to mitigate the growing health burden of stroke in the Philippines.
The GAIN trial: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303).
Dooley, Katharine , Clark, Amanda, Ngo, Zoe, Carvalho, Filipe La Fuente De, Sundi, Debasish , Correa, Andres, Delacroix, Scott Edward, Kates, Max Re, O'Malley, Padraic, Tan, A., Berg, S., Woods, Michael, Galsky, Matthew D. , Rosenberg, Jonathan E., Pietzak, Eugene J , Ballman, Karla V. , Correa, Andres F. , Delacroix, Scott Edward , Kates, Max , Westerman, Mary E. , Rosenberg, Jonathan E

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps909 Get It

TPS909 Background: BCG-Exposed NMIBC (a high grade recurrence within 24 months of prior BCG, but not meeting “unresponsive” criteria) is a large patient population with a critical need for more effective treatment strategies that prevent the development of BCG unresponsive disease/progression. The current standard of care is re-treatment with BCG alone, but only ~50% of patients derive clinical benefit. While intravesical gemcitabine (with or without docetaxel) is sometimes used, multiple retrospective studies have found that GemDoce is no better than re-treatment with BCG alone for patients with BCG-exposed NMIBC. A chemoimmunotherapy strategy of intravesical Gemcitabine with BCG (GemBCG) combines the two most effective, inexpensive, and commonly used treatments for NMIBC. Based on compelling biologic rationale and preclinical data, a phase I/II (n=52) trial was initiated of GemBCG in BCG-exposed NMIBC (NCT04179162). GemBCG has minimal side effects (3.8% [2/52] with Grade 3 TRAEs (no grade 4/5 seen) with similar side effects and tolerability to BCG alone. GemBCG has a outstanding early efficacy signal (6-month complete response of 97% [28/29] in patients with CIS, compared to ~50% 6-month complete response w/ BCG alone for BCG exposed CIS). GemBCG has promising preliminary longer term efficacy (18-month HG-RFS of 76% compared to ~45-55% reported with BCG alone, GemDoce, and recombinant BCG in BCG exposed NMIBC). Correlative studies support the hypothesis that the addition of gemcitabine to BCG can favorably modulate the tumor immune microenvironment. Methods: Based on the above rationale, we initiated the “GAIN” trial (A032303/ NCT07000084), a prospective, multicenter, open-label phase III study for patients with BCG-exposed NMIBC randomized to either: re-treatment with BCG only (Arm A, SOC) or Gemcitabine + BCG (GemBCG, Arm B). BCG-exposed NMIBC is defined as a high grade NMIBC (Ta, T1, Tis/CIS) that has recurred within 24 months of prior BCG, but NOT otherwise currently meeting BCG unresponsive NMIBC. The primary objective is to compare high grade recurrence-free survival (HG-RFS) between the two treatment arms. Notable aspects of the trial include: (1) the reduced burden on investigators and research teams due to the NCI’s new streamlined data initiative, (2) liberal inclusion/exclusion criteria and pragmatic design to improve generalizability of results, and (3) Cystoscopic biopsies/TURBT at week 13/month 3 for all participants (both CIS and “papillary only”) for multiple reasons including to allow for earlier detection of BCG unresponsive disease for patient safety, increased rigor of the trial, and objectively evaluate urinary biomarkers/urinary tumor DNA. Clinical trial information: NCT04179162 .
Short term intensified pembrolizumab and tivozanib for high-risk renal cell carcinoma: STRIKE! (Alliance A032201).
Burbano, Gabriela Perez , Tan, Alan W.C. , Berg, S., Emamekhoo, Hamid, Zhang, T., Chen, Ronald, Rosenberg, Jonathan E., Galsky, Matthew D. , George, Daniel J., McGregor, Bradley A. , Ballman, Karla V. , Tan, Alan, Gulati, Shuchi , Emamekhoo, Hamid , Robin, Tyler P. , Chen, Ronald C. , Rosenberg, Jonathan E , George, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps577 Get It

TPS577 Background: Pembrolizumab (pembro) for one year following resection of localized high risk clear cell renal cell carcinoma (ccRCC) in a phase 3 trial resulted in improvement in relapse-free survival and overall survival (Choueiri, NEJM 2024). However, 20% of patients still experienced a relapse within 2 years with no biomarker yet identified to predict who will respond to or needs adjuvant therapy. Addition of a tyrosine kinase inhibitor (TKI) to immunotherapy (IO) is a standard of care in metastatic ccRCC, but to date no studies have addressed the addition of a TKI to IO in the adjuvant setting. Subsequently, phase 3 STRIKE! was developed to explore the benefit of 6 months of tivozanib (tivo) added to pembro vs pembro alone in the adjuvant setting for resected high risk ccRCC. Methods: Eligible patients have an ECOG performance status ≤2 and a histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features after complete resection of the primary tumor, with pathology revealing pT2 grade 4 disease or any grade ≥ T3 or TxN1. Patients are also eligible if they developed metastasis within a year after resection and then underwent resection, definitive radiation or ablation of solid, isolated, soft tissue metastases (excluding brain and bone lesions) with no evidence of active disease (M1NED). Patients will be randomized 1:1 to intravenous pembro for 48 weeks with or without the addition of tivo 1.34 mg by mouth daily D1-21 q28D for 6 months stratified by stage (T2T3 vs T4/N1 vs M1NED) . With no limit on dose holds or interruptions of tivo, dose reductions of tivo to 0.89 mg D1-21 q28D or tivo 0.89 mg every other day are allowed. No dose reductions of pembro are permitted. Following baseline imaging to confirm no disease, imaging is performed every 12 weeks for first year, every 16 weeks for second year, every 24 weeks for third year and then annually until 5 years after registration or progression. The primary endpoint will be disease-free survival (DFS) as assessed by investigator, with secondary endpoints being overall survival, safety and tolerability. The study will enroll 1040 patients to detect a minimum detectable hazard ratio of 0.67 (24-month DFS 84% in experimental arm) with 90% power. Quality of life analysis will compare global quality of life and fatigue between the two arms. Imaging and specimens will be banked for future research. The study opened to accrual in April 2025 and at this time 106 patients have enrolled. Clinical trial information: NCT06661720 .
ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).
Kilari, Deepak, Ballman, K., Gelmann, Edward P. , Zarrabi, Kevin , Baghaie, Shiva, Sumey, Christopher , Nguyen, Paul, Montgomery, R Bruce, Berg, S., Tan, Alan W.C. , Jacene, H., Chen, Ronald C., Beltran, Himisha, Morris, Michael J., Galsky, Matthew D. , Rosenberg, Jonathan E., McKay, Rana R., Kilari, Deepak , Hillman, David W. , Bryce, Alan H. , Rose, Brent Shane , Tan, Alan, Jacene, Heather A. , Chen, Ronald C., Morris, Michael J. , Rosenberg, Jonathan E , McKay, Rana R.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps290 Get It

TPS290 Background: Landmark randomized trials established the survival benefit of adding D to ADT in mCSPC. Building on this foundation, subsequent trials (PEACE-1 and ARASENS) demonstrated further survival improvements when androgen receptor pathway inhibitors (ARPI) were added to the ADT + D backbone. However, the independent contribution of D within the triplet regimen remains unclear given lack of prospective evaluation. Additionally, tumor suppressor gene (TSG) alterations involving TP53, PTEN, and RB1 are frequently observed in PC and are associated with aggressive biology and poor outcomes, providing an opportunity to enhance prognostic accuracy and optimize selection of candidates for treatment intensification. We hypothesize that adding D to ADT plus A will improve survival compared to ADT + A in mCSPC and stratification by TSG status may identify different treatment effects across molecular subgroups. Methods: ASPIRE is an open-label, two-arm, randomized phase 3 study to assess the benefit of D added to ADT plus A for patients with mCSPC. Eligible patients include those with confirmed adenocarcinoma of the prostate with evidence of distant metastatic disease on conventional imaging and are appropriate to receive D. Patients with metachronous low-volume disease or PSMA-PET only disease are excluded. Candidates must have next-generation sequencing (NGS) results from a CLIA-certified tissue test available for TSG status stratification at registration. Eligible patients will receive ADT plus A (240 mg PO daily) +/- D for up to 6 cycles until progression of disease by PCWG3/RECIST version 1.1 criteria. Prior therapy with ADT (with or without ARPI) initiated within 120 days before registration is permitted. The primary endpoint is overall survival (OS). Secondary endpoints include OS by TSG status; radiographic progression-free survival (rPFS); time to castration resistance; symptomatic skeletal event–free survival; time to worsening of disease-related symptoms (NCCN-FACT FPSI-17); safety and tolerability (CTCAE v5.0); PSA90 response at 6 weeks and 6 months; time to PSA progression; and objective response rate in patients with measurable disease. The study will enroll 1200 patients and is currently actively accruing patients. Clinical trial information: NCT06931340 .